An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Someone on a forum wrote that they’ve been taking semaglutide for almost a year through a program called HERS, lost 32 pounds so far, and still want to lose about 25 more. They say they’re already on the highest dose their program offers, but they still have “food noise” — the urge or thinking about food — and are wondering whether to switch to tirzepatide (sometimes called tirz) even though it looks pricey. They’re asking if others faced the same choice after a year. Semaglutide is the active drug in medicines you’ve probably heard of: Ozempic and Wegovy. In plain terms, it copies a hormone your gut makes after you eat that tells your brain you’re full, slows how quickly your stomach empties, and helps control blood sugar. Because of those effects, semaglutide often reduces appetite and leads to weight loss for many people. Doctors prescribe it for type 2 diabetes and for weight management at different doses. The person’s report is an individual experience, not a clinical trial. Clinical studies show semaglutide can produce substantial weight loss for many people, but results vary. Some people keep losing or maintain weight on the highest approved doses, while others hit a plateau where the drug helps but doesn’t fully stop food thoughts or bring them to their target weight. Tirzepatide is a different drug that acts on two gut hormone targets instead of one, and in clinical trials it produced larger average weight loss than semaglutide. But comparing an individual’s real-world experience to trial averages isn’t exact; cost, side effects, and access all matter. Why this matters is practical. If semaglutide has already helped someone lose a significant amount, it’s doing useful work for health and motivation. But hitting a plateau is common, and people who still have strong food cravings might consider alternative strategies: behavioral support, adjusting diet and exercise, checking for other medical factors, or discussing switching medications with their clinician. Tirzepatide may be more effective for some, but it’s more expensive and may not be covered the same way by insurance or programs like HERS. There are important cautions. Both semaglutide and tirzepatide can cause nausea, diarrhea, stomach pain, and other side effects. Long-term effects are still being studied, and not everyone responds the same way. You shouldn’t change medications without talking to your prescribing clinician. Cost and access are real barriers; a more effective drug isn’t necessarily the best choice if you can’t afford consistent treatment. Also, anecdotal reports don’t replace medical advice or data from controlled studies. Bottom line: Losing 32 pounds on semaglutide is a meaningful result, but hitting a plateau and still feeling food urges is common; switching to tirzepatide might help more for some people, but it brings higher cost and its own risks, so discuss options with your doctor and consider behavioral and lifestyle supports alongside any medication change.
Source: r/Semaglutide